TTUHSC School of Medicine
HomeSchool of MedicineInternal MedicineFaculty




Profile for Sharma Prabhakar

Sharma Prabhakar

Sharma Prabhakar

  • Professor of Medicine and Physiology
  • Vice-Chair
  • Vice-Chairman, Department of Medicine
  • Chief, Division of Nephrology and Hypertension
  • Director of Nephrology Services. University Medical Center
Office Phone: 806-743-4072
Email: sharma.prabhakar@ttuhsc.edu
Mail Address: 3601 4th St Stop 9410
Lubbock TX 79430-9410

Positions:

  • Professor of Medicine and Physiology, Texas Tech University Health Sciences Center Lubbock, TX 2007-Present
  • Vice-Chair, Texas Tech University Health Sciences Center Lubbock, TX 2006-Present
  • Vice-Chairman, Department of Medicine, Texas Tech University Health Sciences Center 2006-Present
  • Chief, Division of Nephrology and Hypertension, Texas Tech University Health Sciences Center Lubbock, TX 2005-Present
  • Director of Nephrology Services. University Medical Center, University Medical Center Lubbock, TX 1998-Present

Post Doctoral Education:

  • Renal Research Fellow: Houston VAMC and Baylor College of Medicine, 1990
  • Resident in Internal Medicine: Baylor College of Medicine, 1989
  • Renal Fellow: University of Texas Health Sciences Center, 1987
  • Fellow in Nephrology: All-India Institute of Medical Sciences, 1983
  • Resident in Internal Medicine: Osmania General Hospital, 1981

Education:

  • MBA: Rawl's College of Business Adminstration, Texas Tech University, 2005
  • MD: Gandhi Medical College, 1977
  • MD: Rajiv Gandhi Univ Of Hsc, 1976

Selected Publications:

  • Srisung, Weeraporn & Jamal, Faisal & Prabhakar, Sharma (2015) Synthetic cannabinoids and acute kidney injury - A Case Series. Proceedings (Baylor Univ Med Center), 28, 4, 475-477.
  • , Matsui & Prabhakar, Sharma November (2015) Commentary on: Excess 25-hydroxyvitamin D3 exacerbates tublointerstitial injury in mice by modulating macrophage phenotype. Faculty1000Prime, 88, 5, 1013-29.
  • , Sorenson-Zender & Prabhakar, Sharma November (2015) Commentary on: Zinc-α2-Glycoprotein exerts antifibrotic effects in kidney and heart. Faculty1000Prime, 26, 11, 2659-68.
  • Prabhakar, Sharma & Limsuwat, Chok September (2012) Reversible Renal Glycosuria in Acute Interstitial Nephritis American Journal of Medical Sciences, 344, 3, 245-247.
  • Hobin, J & Deschamps, A & Bockman, R & Cohen, S & Dechow, P & Eng, C & Galey, W & Morris, M & Prabhakar, Sharma & Raj, U & Rubenstein, P & Smith, J & Stover, P & Sung, N & Talman, W & Galbraith, R & , April (2012) Engaging basic scientists in translational research: identifying opportunities, overcoming obstacles Journal of Translational Medicine , 10, 72.

Selected Presentations:

  • Cardio-Renal Syndrome. GMCGA Annual Medical Symposium, Hyderabad, India; 2015.
  • Medical Research in Hispanic Health Issues. Lubbock Hispanic Faculty and Staff Association, Lubbock, Texas; 2015.
  • Correlation of pulse pressure to renal functional parameters in a cross sectional study of general population - The Texas Kidney Study. American Society of Nephrology (ASN), San Diego, California; November 2015.
  • Modulation of Akt/AS160 phosphorylation mediates insulin resistance in a rat model of metabolic syndrome. American Society of Nephrology (ASN), San Diego, California; November 2015.
  • Regulation of parathyroid hormone in a murine model of metabolic syndrome. Washington, D.C.; April 2015.

Selected Contracts and Grants:

  • Prolyl hydroxylase inhibitor (PHI) phase 3 program in anemia associated with chronic kidney disease and in dialysis study. 2015-
    Awarded by Private
    in the amount of $0
    Principal

  • Randomized, placebo-controlled, parallel-group, double-blind study of H.P. Acthar® Gel (Acthar) in treatment-resistant subjects with persistent proteinuria and nephrotic syndrome due to idiopathic membranous nephropathy (iMN) 2011-
    Awarded by Private
    in the amount of $0
    Principal

  • A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease. 2015-2017
    Awarded by Private
    in the amount of $0
    Principal

  • A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care. 2015-2017
    Awarded by Private
    in the amount of $0
    Principal

  • Natural products-biological effects and therapeutic potential -2016
    Awarded by
    in the amount of $0


Selected Awards:

  • Best Doctors in America, 2015.
  • Distinguished Faculty Award, Telangana State, India, 2015.
  • Best Doctors in America, 2014.
  • Co-Chair, Organizing Committee and Keynote Speaker, ICN, 2013.
  • Chair of the Organizing Committee, 3rd World Congress on Diabetes and Metabolism, 2012.

Selected Scheduled Teaching:

  • Didactic Lectures - Renal Fellows - 2015
  • Introduction to System Disorders - 2015
  • MSIII - Core Curriculum - 2015
  • Sub-specialty Lectures - Residents - 2015

Selected Directed Student Learning:

  • External Examiner and Thesis Reviewer 2015 - Present

Selected Non-Credit Instruction Taught:

  • Peri-operative AKI - 2015
  • Renal Function and Disease in the Elderly. - 2015
Date last updated: 8/26/2016
Research Interests

Diabetic Nephropathy
Metabolic Syndrome
Animal Models of Human Disease

Teaching Interests

Hypertension
Diabetes mellitus
Chronic kidney Disease

©